ABVC BIOPHARMA, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ABVC BIOPHARMA, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $509.6K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $152.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $969.8K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $355.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $483.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $701.7K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $7.0K | May 15, 2020 |
| FY2015 | Sep 30, 2015 | $3.4K | Nov 27, 2015 |
| FY2015 | Sep 30, 2014 | $0 | Nov 27, 2015 |
| FY2015 | Sep 18, 2014 | $0 | Nov 27, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $508.8K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($149.6K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $683.4K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $350.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $464.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $681.6K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($178.3K) | May 15, 2020 |
| FY2017 | Sep 30, 2016 | ($32) | Jan 16, 2018 |
| FY2015 | Sep 30, 2015 | $2.8K | Nov 27, 2015 |
| FY2015 | Sep 30, 2014 | $0 | Nov 27, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.91M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($4.90M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($7.79M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($16.42M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($12.84M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($10.59M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.93M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($6.06M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($4.24M) | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | ($4.07M) | Jan 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.15M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($4.71M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($6.77M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($15.11M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($11.71M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($8.51M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.46M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($2.78M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($4.14M) | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | ($4.00M) | Jan 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.1K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $179.3K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.06M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.69M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $549.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.05M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $988.7K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $3.17M | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | $3.15M | Jan 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.89M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $2.26M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $5.37M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $6.07M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.07M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.59M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $811.7K | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | $707.1K | Jan 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.99M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($1.81M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($4.19M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($7.40M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($7.60M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.56M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.13M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($900.5K) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($1.49M) | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | ($1.60M) | Jan 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $21.2K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $119.7K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $17.5K | Mar 31, 2023 |
| FY2013 | Sep 30, 2013 | $0 | Apr 16, 2015 |
| FY2013 | Sep 30, 2012 | $350 | Apr 16, 2015 |
| FY2012 | Sep 30, 2011 | $29.8K | Apr 15, 2015 |
| FY2011 | Sep 30, 2010 | ($1.4K) | Dec 28, 2011 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.06M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $7.54M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $7.78M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $9.58M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $13.70M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $11.61M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.93M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $5.94M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $2.64M | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | $2.75M | Jan 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.76M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $6.82M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $6.53M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $6.34M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.05M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $11.28M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $4.40M | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | $4.15M | Jan 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.11M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.23M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.55M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.10M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $8.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.44M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($151.0K) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($5.66M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($1.76M) | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | ($1.39M) | Jan 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.86M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($68.95M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($64.05M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($54.90M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($38.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($25.64M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.85M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($12.21M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($15.78M) | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | ($15.40M) | Jan 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $681.5K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $248.4K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $60.2K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $85.3K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $144.3K | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $226.7K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $93.3K | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | $204.9K | Jan 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Jan 16, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Jan 16, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Jan 16, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Jan 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.05M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 13.87M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 7.94M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 3.29M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 24.42M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 24.42M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 19.48M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 11.88M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | 213.75M | Apr 15, 2019 |
| FY2017 | Sep 30, 2017 | 213.75M | Jan 16, 2018 |